Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).

导出原文传递

翻译打印收藏纠错

第一作者： Makoto,Nishio

第一单位： Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: mnishio@jfcr.or.jp.

作者： Makoto,Nishio ^[1] ; Shunichi,Sugawara ^[2] ; Shinji,Atagi ^[3] ; Hiroaki,Akamatsu ^[4] ; Hiroshi,Sakai ^[5] ; Isamu,Okamoto ^[6] ; Koichi,Takayama ^[7] ; Hidetoshi,Hayashi ^[8] ; Yuki,Nakagawa ^[9] ; Tomohisa,Kawakami ^[9]

作者单位： Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address: mnishio@jfcr.or.jp. ^[1] Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan. ^[2] Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan. ^[3] Department of Internal Medicine III, Wakayama Medical University, Wakayama, Japan. ^[4] Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan. ^[5] Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ^[6] Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. ^[7] Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan. ^[8] Chugai Pharmaceutical Co, Ltd, Tokyo, Japan. ^[9]

关键词 Asian patients Cancer immunotherapy Japan Programmed death-ligand 1 TECENTRIQ